Dichloroacetate (DCA) and Brain Cancer (Glioblastoma): Patient-Friendly Research Guide

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Dichloroacetate (DCA) and Brain Cancer (Glioblastoma): A Patient-Friendly Research Overview

If you or a loved one has Brain Cancer (Glioblastoma) and you've heard about Dichloroacetate (DCA), this guide explains what the research actually shows in plain language. We believe patients deserve honest, clear information — not hype, not dismissal. This is a research summary only. Always work with your neuro-oncologist.

What is Dichloroacetate (DCA)?

Dichloroacetate (DCA) is classified as a Metabolic / Pyruvate Dehydrogenase Kinase Inhibitor. In simple terms, it works by: Inhibits PDK; shifts glucose metabolism from glycolysis to OXPHOS; reactivates mitochondria in cancer cells; pro-apoptotic...

Its current regulatory status: Not FDA-approved; investigational for cancer and metabolic disorders

Why Are Brain Cancer Patients Asking About Dichloroacetate (DCA)?

Researchers and patients with Brain Cancer have explored Dichloroacetate (DCA) because of its specific mechanisms that may be relevant to Brain Cancer biology. This has generated both scientific publications and patient community interest.

What the Research Actually Shows

Evidence level: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity

This means: There is scientific research specifically examining this combination, providing more than just theoretical interest.

Safety in Plain Language

What you should know about Dichloroacetate (DCA) safety: Peripheral neuropathy is dose-limiting; reversible with dose reduction; thiamine supplementation may mitigate

Important: even compounds with favorable safety profiles can have risks in Brain Cancer patients due to interactions with treatment or disease-related organ changes.

Questions to Bring to Your Neuro-Oncologist

  • Has Dichloroacetate (DCA) been studied for Brain Cancer? What does the evidence show?
  • Could Dichloroacetate (DCA) interact with my current Brain Cancer treatment?
  • Are there clinical trials involving Dichloroacetate (DCA) that I might be eligible for?
  • What monitoring would be needed if I were to try Dichloroacetate (DCA)?
  • What are the alternatives that have stronger evidence?

How to Research Further

For continued research: PubMed (pubmed.ncbi.nlm.nih.gov) for peer-reviewed studies, ClinicalTrials.gov for active trials, and insightswarm.ai for a personalized AI-generated research report tailored to your specific case.


Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

Can Dichloroacetate (DCA) cure Brain Cancer?

No compound has been proven to cure Brain Cancer (Glioblastoma), and Dichloroacetate (DCA) is no exception. The current evidence for Dichloroacetate (DCA) in Brain Cancer is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity. Be cautious of any source claiming a cure.

Is Dichloroacetate (DCA) worth trying for Brain Cancer?

Whether Dichloroacetate (DCA) is worth considering for your specific Brain Cancer case is a decision that requires your neuro-oncologist's assessment. The published research (Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity) can inform that conversation, but individual factors matter enormously.

Where can I learn more about Dichloroacetate (DCA) for Brain Cancer?

Reliable sources: PubMed for peer-reviewed research, ClinicalTrials.gov for trials, your neuro-oncologist, and insightswarm.ai for a personalized research report. Be critical of forums and social media, which often amplify anecdotal reports.